Spark Therapeutics (ONCE) Tops Q3 EPS by 74c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Spark Therapeutics (ONCE) PT Raised to $65 at Wedbush
November 8, 2017 10:10 AM ESTWedbush raised its price target on Spark Therapeutics (NASDAQ: ONCE) to $65.00 (from $48.00) while maintaining a Underperform rating on higher-than-expected pricing estimates for Luxturna.
... MoreSpark Therapeutics (ONCE), Pfizer (PFE) Amend Pact for Investigational SPK-9001 in Hemophilia B
November 7, 2017 7:16 AM ESTSpark Therapeutics (NASDAQ: ONCE) and Pfizer Inc. (NYSE: PFE) today announced they have entered into an amendment to their license agreement for SPK-9001, an investigational gene therapy for hemophilia B. Spark Therapeutics will enroll up to five additional participants in the current Phase 1/2 clinical trial who will receive SPK-9001 manufactured using an enhanced process to test its comparability to the SPK-9001 received by the first 10 participants enrolled in the ongoing trial.
One of the up to five participants has already received SPK-9001 manufactured... More
